← All indications
Kidney Failure, Chronic
The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
Subtype terms (1)
More specific conditions that are subtypes of Kidney Failure, Chronic in the MeSH hierarchy.
Drugs by status
Approved for this indication (24)
Phase 4 trials (169)
- elbasvir
- hydroxychloroquine
- arginine
- amino acids
- sodium citrate
- sodium bicarbonate
- nicorandil
- rivaroxaban
- alendronic acid
- calcifediol
- insulin glargine
- hepatitis b vaccine (recombinant)
- daclizumab
- captopril
- paritaprevir
- citric acid
- iopromide
- cyclosporine
- minocycline
- epoetin
- gabapentin
- alprostadil
- tinzaparin
- sevelamer
- roxadustat
- nadroparin
- polymyxin b sulfate
- immune globulin (human)
- pneumococcal 13-valent conjugate vaccine
- ferric citrate
- +139 more
Phase 3 trials (64)
- ringer's lactate
- Upacicalcet
- cobalamin
- pravastatin
- meropenem
- xylitol
- taurolidine
- fentanyl
- febuxostat
- homocysteine
- bifidobacterium animalis
- pancrelipase
- iron hydroxide adipate
- dalteparin
- nabilone
- metoprolol
- levobupivacaine
- phenprocoumon
- clazakizumab
- tocilizumab
- vitamin k2
- sodium propionate hydrate
- pomegranate
- dasabuvir
- b multivitamins
- sotagliflozin
- white wine
- flurandrenolide
- azathioprine
- zinc
- +34 more
Phase 2 trials (134)
- dextrose
- rhizoma atractylodis macrocephalae
- bortezomib
- ghrp-1/ag
- vadadustat
- ranitidine
- efalizumab
- fenoldopam
- corn
- flavanoids
- allogeneic bone marrow
- ferric saccharose
- etanercept
- mdgn201
- thymalfasin
- calcium carbonate
- turmeric
- lactobacillus delbrueckii
- genz-644470
- phytonadione
- bone autograft
- rosuvastatin
- rhizoma dioscoreae
- bardoxolone
- revefenacin
- fish oil
- l-alanyl-l-glutamine
- nedosiran
- milk thistle
- acacia
- +104 more
Phase 1 trials (233)
- corticotropin
- lobeglitazone
- pasireotide
- imarikiren
- naloxegol
- paclitaxel
- amisulpride
- mbx 2109
- ar882
- azd0780
- jnj-64565111
- ctap201
- pitolisant
- telotristat ethyl
- safinamide
- cabozantinib
- siponimod
- s-892216
- Mezigdomide
- pradigastat
- topiramate
- difelikefalin
- azd3427
- methylnaltrexone
- Milvexian
- t lymphocytes
- seltorexant
- plerixafor
- zasocitinib
- encenicline
- +203 more
Other trials (39)
- allogeneic pancreatic islet cells
- polysulfone
- bifidobacterium longum
- whey protein
- lidocaine
- chitosan
- mannitol
- nebivolol
- enterococcus faecium
- zidovudine
- teriparatide
- ibutamoren
- nitroglycerin
- albuterol
- fiber
- beta-hydroxyisovaleric acid
- hemopoietic stem cell
- polymethylmetacrylate
- lactococcus lactis
- kibow biotics
- ganciclovir
- glucagon
- Lactobacillus acidophilus
- lactobacillus reuteri
- tamsulosin
- thiram
- benazepril
- nandrolone phenpropionate
- clobetasol
- lactobacillus salivarius
- +9 more
Organizations
Organization Involved with Phase 4 Indications (198)
- University of London
- The Japan Kidney Foundation
- Poznan University
- Sun Yat-Sen University
- National Institute for Health Research, United Kingdom
- Universidade Estadual de Londrina
- General Electric
- Shin Kong Wu Ho-Su Memorial Hospital
- Harvard University
- Allegheny Health Network
- University of Tehran
- Dankook University
- University of Wisconsin
- Cedars-Sinai Medical Center
- Northwestern University
- Kumamoto University
- Yonsei University
- Government of Korea
- Wright State University
- Johns Hopkins University
- University of Western Australia
- Keryx
- NausLife Hemodialysis Clinics
- Creighton University
- University of Cincinnati
- Hoosier Cancer Research Network
- Cathay General Hospital
- Instituto Nacional de la Nutrición Salvador Zubiran
- Genentech
- State University of Londrina
- +168 more
Organization Involved with Phase 3 Indications (123)
- Ineos Healthcare Limited
- University of Campinas
- Affymax
- United States Army
- Dalian Medical University
- University of Sydney
- AstraZeneca
- China Agricultural University
- Spectra Clinical Research
- Canadian Institutes of Health Research (CIHR)
- Drexel University
- Utrecht University
- FibroGen
- Jilin University
- Capital Medical University
- Translational Research Informatics Center, Kobe, Hyogo, Japan
- Toray Industries, Inc
- Instituto Nacional de Cardiologia Ignacio Chavez
- Ash Access Technology
- Aventis
- Kuala Lumpur General Hospital
- Meihekou Central Hospital
- University of Chile
- University Clermont Auvergne
- IKDRC, Civil Hospital, Ahmedabad
- University of New Mexico
- The Alfred Hospital
- Pamlab
- Qingdao University
- National Institute of Allergy and Infectious Diseases (NIAID)
- +93 more
Organization Involved with Phase 2 Indications (97)
- Calliditas Therapeutics
- Pirogov Russian National Research Medical University
- Tel Aviv University
- George Washington University
- Pulmonary and Critical Care Assoc. of Baltimore
- Deltanoid Pharmaceuticals
- Cooperative Clinical Trials in Pediatric Transplantation
- Hyundai
- Hebrew University
- Aronora, Inc.
- Columbia University
- Celerion
- National Institutes of Health (NIH)
- Medical University of Vienna
- Leadiant Biosciences, Inc.
- PathWest Laboratory Medicine WA
- Noxxon AG
- Opko
- Tufts University
- Cubist
- National Center for Research Resources (NCRR)
- Russian Academy of Medical Sciences
- Vanderbilt University
- Orlando Clinical Research Center
- National Heart, Lung, and Blood Institute (NHLBI)
- Zhejiang University
- Ionis Pharmaceuticals, Inc.
- The Rogosin Institute
- Wayne State University
- Chang Zheng Hospital
- +67 more
Organization Involved with Phase 1 Indications (35)
- Savient Pharmaceuticals
- Pharmaceutical Research Associates, Inc. (PRA)
- Royan Institute
- A.O. Ospedale Papa Giovanni XXIII
- Assign Clinical Research GmbH
- University of California, San Francisco
- University of Arkansas
- True North Therapeutics
- Youngstown State University
- WiSP GmbH
- University of Brescia
- Quest Diagnostics
- Basilea Pharmaceutica
- ABF Pharmaceutical Services GmbH
- GlaxoSmithKline
- Debiopharm
- Prolong Pharmaceuticals
- InCROM
- Cara Therapeutics
- University of Kansas
- Mazandaran University of Medical Sciences
- University of Chicago
- University of Florida
- Mayo Clinic
- SK Chemicals
- Akros
- Tetraphase Pharmaceuticals
- Chelsea Therapeutics
- GW Pharmaceuticals Ltd.
- Guerbet
- +5 more
Organization Involved with Other Experimental Indications (60)
- Indiana University
- Tung's Taiching MetroHarbor Hospital
- University of Utah
- Icahn School of Medicine at Mount Sinai
- Probiotical S.p.A.
- Ege University
- Henry Ford Health System
- Alberta Heritage Foundation for Medical Research
- University of Gothenburg
- Government of Sudan
- University of Minnesota
- Dong-A University
- Government of Hong Kong
- Centro Universitario de Tonalá
- Worldwide Clinical Trials
- Hospital, Saintes, France
- University of Maryland
- CH DUNKERQUE
- The Physicians' Services Incorporated Foundation
- University of Tuebingen
- University of Illinois
- Ben Gurion University
- University of Khartoum
- Universidad de Colima
- Los Angeles Biomedical Research Institute
- University of Toulouse
- University Putra Malaysia
- University of Ljubljana
- New Orleans Center for Clinical Research
- "Maggiore della Carità" Hospital
- +30 more